Clinical Trial Update: Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating dalpiciclib in combination with letrozole for recurrent ovarian carcinoma in HR+/HER2-negative gynecologic solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Ovarian Carcinoma

Drugs mentioned

• Dalpiciclib (dalpiciclib)
• Letrozole (letrozole)

Snippet

Sponsor: Fengzhi Feng | Conditions: Recurrent Ovarian Carcinoma | Phase 2 | Status: UNKNOWN